Lipedema and Insulin Resistance: What the Research Shows About Metabolic Dysfunction in Lipedema Tissue and Why It Matters for Diagnosis, Diet, and Treatment

If your blood sugar fluctuates badly, you carry weight that diet does not move, and your fasting insulin is high despite a normal-range fasting glucose — and you also have the disproportionate, painful, easily-bruising lower-body fat distribution typical of lipedema — this is not a coincidence. Insulin resistance is significantly more common in women with lipedema than in BMI-matched women without lipedema, and the relationship between the two conditions is now one of the more active areas of lipedema research.

This guide summarises what the published research shows about insulin resistance in lipedema, the mechanisms by which lipedema-affected adipose tissue appears to behave differently from ordinary fat, what this means clinically — for diagnosis, dietary planning, GLP-1 response, and progression — and what the strongest current evidence suggests is most effective.

Is insulin resistance more common in lipedema?

Yes — multiple studies have found that women with lipedema have higher rates of insulin resistance than BMI-matched women without lipedema, and that insulin resistance correlates with lipedema stage and disease severity. The relationship is not explained by body mass index alone. It appears to be intrinsic to the metabolic behaviour of lipedema-affected adipose tissue.

Key findings across the published literature:

• A 2021 study in Obesity Facts (Torre et al.) reported significantly higher HOMA-IR (a standard measure of insulin resistance) in lipedema patients compared with BMI-matched controls
• Reviews in International Journal of Molecular Sciences (2020, 2022) describe adipocyte hypertrophy, inflammation, and impaired insulin signalling as features of lipedema-affected fat
• Multiple studies report an elevated prevalence of metabolic syndrome components — high triglycerides, low HDL, central adiposity, hypertension, and impaired glucose regulation — in lipedema cohorts
• Research summarised in the 2024 Standard of Care for Lipedema in the United States (Kruppa, Herbst, et al.) explicitly notes the elevated rates of insulin resistance, type 2 diabetes risk, and PCOS co-occurrence in lipedema populations
• A growing body of evidence ties lipedema-affected tissue to chronic low-grade inflammation, which is itself a known driver of insulin resistance independent of body weight

The clinical implication is that a normal fasting glucose does not rule out a metabolic problem in someone with lipedema. Fasting insulin and HOMA-IR are more sensitive markers in this population.

Why is lipedema-affected fat metabolically different?

Lipedema-affected adipose tissue does not behave like ordinary subcutaneous fat. Several mechanisms have been described in the research:

1. Adipocyte hypertrophy and dysfunction

Biopsy and imaging studies consistently show that fat cells in lipedema-affected tissue are enlarged (hypertrophic) rather than simply more numerous. Hypertrophic adipocytes are metabolically dysfunctional — they secrete more pro-inflammatory cytokines (TNF-α, IL-6), have impaired insulin signalling, and contribute to systemic insulin resistance even when overall body fat is moderate.

2. Chronic low-grade inflammation

Lipedema tissue shows persistent inflammatory infiltrate on biopsy. Macrophage accumulation, elevated cytokines, and fibrotic remodelling are described in multiple histological studies. Chronic inflammation interferes with insulin receptor signalling at a cellular level — a mechanism well established in obesity research and increasingly described as central to lipedema pathophysiology. (Lipedema and inflammation covers this in more detail.)

3. Microvascular and lymphatic dysfunction

Capillary fragility and impaired lymphatic clearance — themselves cardinal features of lipedema — contribute to interstitial fluid accumulation and tissue hypoxia. Hypoxic adipose tissue is more inflamed and more insulin-resistant. The microvascular changes that drive easy bruising in lipedema and persistent swelling also contribute to the metabolic phenotype.

4. Hormonal interaction

Lipedema is overwhelmingly female and characteristically appears at hormonal transitions — puberty, pregnancy, perimenopause. Oestrogen, progesterone, and cortisol all interact with insulin sensitivity. Women with lipedema also have elevated rates of PCOS and Hashimoto's thyroiditis, both of which are independently associated with insulin resistance. The overlap is too consistent to be coincidence.

5. Resistance to caloric restriction

Lipedema-affected fat does not respond to weight loss the way ordinary adipose tissue does — a defining clinical feature. Repeated weight loss attempts that fail to mobilise the affected tissue can drive weight cycling, which itself worsens insulin resistance. Years of yo-yoing can leave a patient more metabolically dysregulated than when they started. (Lipedema and weight loss and the diagnostic delay article cover this dynamic.)

Why this matters clinically

Recognising insulin resistance as part of the lipedema picture changes several practical things.

It supports the diagnosis

A patient with disproportionate lower-body fat distribution, easy bruising, hormonal pattern of onset, family history, and insulin resistance at a body weight that would not normally produce it has a clinical picture that is harder to dismiss as ordinary obesity. Fasting insulin and HOMA-IR are inexpensive and easy to order. They are not diagnostic of lipedema on their own — but they help build the case.

It changes dietary recommendations

If insulin resistance is present, simple caloric restriction is rarely the most effective dietary strategy. The published evidence on lipedema-specific nutrition consistently favours approaches that reduce post-prandial insulin spikes:

• Low-glycaemic, anti-inflammatory diets (Mediterranean-pattern, RAD-style) — see the lipedema diet guide
• Lower-carbohydrate or ketogenic approaches — discussed in lipedema and the keto diet
• Reduced added sugar — covered in sugar and lipedema
• Time-restricted eating in some patients, where it does not interact badly with adrenal symptoms

The mechanism is consistent across approaches: lower the chronic insulin signal, reduce inflammation, improve metabolic flexibility. None of these reverse lipedema. They can meaningfully improve symptoms, slow progression, and address the metabolic component that diet alone cannot if it is not targeted.

It explains GLP-1 response patterns

GLP-1 receptor agonists (semaglutide, tirzepatide) work in part by improving insulin sensitivity. Many lipedema patients report meaningful improvements in non-lipedema fat, energy, and metabolic markers on GLP-1s — without proportional improvement in lipedema-affected tissue. This is consistent with the picture of two metabolically distinct fat compartments coexisting in the same person: GLP-1s address the insulin-resistant ordinary adiposity component well, but the lipedema-affected tissue retains its characteristic resistance to mobilisation.

It changes pharmacological options

Metformin is occasionally used in lipedema patients with documented insulin resistance, particularly where PCOS co-occurs. Evidence is observational rather than from large randomised trials, but the rationale is mechanistic: improving insulin sensitivity addresses one of the drivers of progression.

The 2024 US Standard of Care discusses metformin as a reasonable consideration in lipedema patients with metabolic syndrome features, with the standard caveats about individual clinical judgement.

It is a progression risk factor

Insulin resistance is not just a consequence of lipedema — it appears to contribute to its progression. Higher inflammatory load, hypertrophic adipocytes, and impaired metabolic flexibility all accelerate the structural changes that take a patient from stage 1 to stage 2 to stage 3 over time. Addressing insulin resistance is therefore one of the few modifiable drivers of long-term outcome.

What the strongest evidence supports

Across the published research and clinical guidelines, a consistent set of recommendations emerges for women with lipedema and documented or suspected insulin resistance:

1. Test fasting insulin and HOMA-IR, not only fasting glucose. A normal fasting glucose with elevated fasting insulin is a common pattern in early-stage metabolic dysfunction and is missed by glucose alone
2. Anti-inflammatory, lower-glycaemic diet as the dietary baseline — Mediterranean-pattern, RAD, or modified low-carb depending on individual response
3. Resistance training — improves insulin sensitivity at the muscle level and is well-tolerated in most lipedema patients. Exercise and lipedema and water exercise cover what works in this population
4. Compression and lymphatic support — improves the microvascular environment that drives part of the inflammatory and metabolic load. See the compression guide and self-MLD article
5. Sleep and stress management — both are major modulators of insulin sensitivity. Lipedema and sleep and lipedema and stress cover the specific dynamics
6. Pharmacological options where appropriate — metformin and GLP-1s in selected patients, under specialist supervision
7. Tracking — symptom, weight, and where possible metabolic markers over time. The relationship between dietary changes, compression use, sleep, and metabolic markers is highly individual. Why tracking matters for lipedema covers this in detail

What to ask your clinician

If you have lipedema or suspect it, and your weight or metabolic picture is not behaving the way generic advice predicts, the following questions are reasonable to bring to a clinician:

• "Can we check my fasting insulin and HOMA-IR, not only fasting glucose and HbA1c?"
• "Could the metabolic component of my picture be relevant to how my body is responding to diet and exercise?"
• "Given that I have lipedema, are there dietary approaches that target insulin resistance specifically that we should discuss?"
• "If my insulin resistance is significant, is metformin or a GLP-1 receptor agonist worth considering for the metabolic and non-lipedema fat components?"
• "Does my PCOS / Hashimoto's / family history of type 2 diabetes change the picture here?"

A clinician familiar with lipedema will recognise these as appropriate. A clinician unfamiliar with it may not — in which case finding a lipedema specialist is often the next step.

Frequently asked questions

Does lipedema cause insulin resistance, or does insulin resistance cause lipedema? The relationship is bidirectional and not fully resolved in the research. Lipedema-affected adipose tissue appears to be intrinsically metabolically dysfunctional — hypertrophic, inflamed, and insulin-resistant at the tissue level — which contributes to systemic insulin resistance. At the same time, systemic insulin resistance and chronic inflammation appear to accelerate lipedema progression. The current consensus is that the two reinforce each other rather than one strictly causing the other.

Can I have lipedema without insulin resistance? Yes. Not all lipedema patients are insulin resistant, particularly in early stages. But the rates are higher than in BMI-matched controls and tend to increase with stage. Testing fasting insulin and HOMA-IR is reasonable in any lipedema patient, particularly those with a family history of type 2 diabetes, PCOS, or metabolic syndrome features.

Is lipedema a form of diabetes? No. Lipedema is a separate condition with a distinct clinical picture. However, women with lipedema are at elevated risk of type 2 diabetes compared with women of equivalent BMI without lipedema, partly because of the elevated rate of insulin resistance, partly because of overlap with PCOS and other endocrine conditions, and partly because of weight gain associated with progression and weight cycling.

What is the best diet for lipedema with insulin resistance? The published evidence and clinical experience converge on anti-inflammatory, lower-glycaemic eating patterns: Mediterranean-style, the RAD (Rare Adipose Disorders) approach, or modified ketogenic in selected patients. The core principles are reducing post-prandial insulin spikes, lowering chronic inflammation, and ensuring adequate protein, fibre, and micronutrients. (Lipedema diet guide covers this in more detail.)

Will metformin reduce my lipedema fat? Metformin is not a treatment for lipedema fat itself. In patients with documented insulin resistance, metformin can improve metabolic markers, support modest weight management of non-lipedema adipose tissue, and possibly reduce the inflammatory load that drives progression. Whether it slows progression in lipedema specifically has not been established in randomised trials. Decisions are individual and should involve a clinician familiar with both lipedema and metabolic medicine.

Will GLP-1 medications work on lipedema fat? GLP-1 receptor agonists (semaglutide, tirzepatide) are effective at reducing ordinary adipose tissue and improving insulin sensitivity in many lipedema patients. They are less effective at reducing the lipedema-affected tissue itself, which is consistent with the picture of two metabolically distinct fat compartments. Many lipedema patients report a more proportionate body shape after GLP-1 use because the non-lipedema fat decreases while the lipedema fat is relatively preserved. Decisions should be made with a knowledgeable clinician.

What blood tests should I ask for if I have lipedema? A reasonable starting panel includes: fasting glucose, fasting insulin (often omitted), HbA1c, lipid panel, TSH and free T4 (and ideally TPO antibodies if Hashimoto's is suspected), CRP, vitamin D, ferritin, and — if indicated — sex hormone panel and testosterone (for PCOS screening). HOMA-IR can be calculated from fasting glucose and insulin.

Does losing weight improve insulin resistance in lipedema? Loss of non-lipedema adipose tissue typically improves insulin sensitivity in lipedema patients, even if the lipedema-affected tissue itself does not change. Compression, anti-inflammatory eating, resistance training, and sleep optimisation also improve insulin sensitivity independent of weight change. The clinical goal is metabolic improvement, not necessarily a specific number on the scale.

This article is for educational purposes only and does not constitute medical advice. If you have lipedema, suspected insulin resistance, or are considering changes to your diet or medication, please consult a qualified healthcare professional with experience in the condition.